Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids
View Patent ↗Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
1. A human immunodeficiency virus comprising an alkyne-modified fatty acid moiety, wherein the moiety is non-naturally occurring, and
wherein the alkyne-modified fatty acid moiety is 15-ethynylpentadecanyl or 12-ethynyldodecanyl.
2. The virus of claim 1 , wherein the virus is HIV-1.
3. The virus of claim 1 , wherein the virus is inactivated.
4. The virus of claim 1 , wherein the virus is attenuated.
5. The virus of claim 1 , wherein the alkyne-modified fatty acid moiety is 15-ethynylpentadecanyl.
6. The virus of claim 1 , wherein the alkyne-modified fatty acid moiety is attached to the virus by an amide or a thioester bond.
7. A composition comprising the virus of claim 1 .
8. The composition of claim 7 , further comprising a pharmaceutically acceptable excipient.
9. The virus of claim 1 , wherein the alkyne-modified fatty acid moiety is 12-ethynyldodecanyl.
10. An in vitro method of producing the human immunodeficiency virus of claim 1 , the method comprising contacting the virus with the alkyne-modified fatty acid moiety in an amount effective to enhance the infectivity of the virus.
11. The method of claim 10 , wherein the virus is in a cell.
12. The method of claim 11 , wherein the cell is a human animal cell or a non-human animal cell.
13. The method of claim 10 , wherein the human immunodeficiency virus is HIV-1.
14. The method of claim 10 , wherein the contacting is performed in a solution comprising at least one of animal serum, amino acids, buffers, fatty acids, glucose, hormones, inorganic salts, lipids, metal ion chelators, peptides, surfactants, trace metals, and vitamins.